Compare Amgen, Inc. (AMGN) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs KeyCorp — how do they compare? Amgen, Inc. trades at $361.92 (market cap $196.12B), while KeyCorp trades at $23.29 (market cap $25.15B). The key difference: Amgen, Inc. is far larger — about 7.8× KeyCorp's market cap, and KeyCorp pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| AMGN | KEY | |
|---|---|---|
Market Cap | $196.12B | $25.15B |
Sector | Health | Financials |
52-Week High | $388.16 | $23.43 |
52-Week Low | $271.18 | $16.78 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KeyCorp (KEY) trades at $23.30, up 0.87% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.42. Revenue rebounded to $7.29 billion in 2025, driving net income to $1.83 billion. Analyst consensus is strongly positive, with a $29.32 price target representing significant upside. Recent news highlights a new $3 billion share buyback program and innovations in business fraud protection.
The outlook for KEY is favorable, supported by earnings momentum, shareholder returns, and analyst optimism. Key opportunities include continued earnings beats and capital return initiatives. Risks involve volatile cash flows, with net cash flow negative in 2025 and 2026, and sensitivity to interest rate changes affecting bank profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
